Viewing Study NCT02887118


Ignite Creation Date: 2025-12-25 @ 5:05 AM
Ignite Modification Date: 2026-03-03 @ 2:25 PM
Study NCT ID: NCT02887118
Status: TERMINATED
Last Update Posted: 2020-07-10
First Post: 2016-06-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dense Red Blood Cells in Sickle Cell Children
Sponsor: Centre Hospitalier Intercommunal Creteil
Organization:

Study Overview

Official Title: Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort
Status: TERMINATED
Status Verified Date: 2020-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: The recruiting centre was no longer presenting new patients for inclusion
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: DREPADENSE
Brief Summary: Quantitative and prognostic evaluation of dense red blood cells in sickle cell children: preliminary single center study from the Creteil pediatric cohort.
Detailed Description: An association between red blood cell density and hemolytic parameters, and clinical manifestations has been demonstrated in adults with sickle cell anemia.

This factor has not been studied in children. The identification of predictive biomarkers of disease severity, especially of specific pediatric complications (cerebral vasculopathy, splenic sequestration, Dactylitis) would be useful for optimal care of the children and early intensification Red blood cell density might be one of these prognostic factors.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: